The annual report tells that: "The Company has been...

The annual report tells that: "The Company has been strengthening its patent portfolio throughout the year .... " We can see that there are new patent applications for both PBT2 (“Processes for the preparation of 8-Hydroxyquinoline Derivatives” ) and PBT434 (“A method of the production) for " synthetic routes ". I wonder if these applications could help to get longer patents for both PBT2 and PBT434. At least PBT2 would need longer time at least now when QU has patented PBT2 to be used in treating resistant bacteria. Why would they apply anything for PBT2 if there is not any smart use for it?
But there was also this report about brain injuries by Prana scientists: Metal chaperones: a novel therapeutic strategy for brain injury? And also this one: Targeting metals rescues the phenotype in an animal model of tauopathy. So there is a need to get a longer patent for PBT2, not only because of Queensland university will be using PBT2 patent.